Point72 Hong Kong LTD Ventyx Biosciences, Inc. Transaction History
Point72 Hong Kong LTD
- $1.34 Billion
- Q2 2025
Shares
2 transactions
Others Institutions Holding VTYX
# of Institutions
119Shares Held
49.7MCall Options Held
70.4KPut Options Held
51.4K-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.9MShares$51.7 Million0.03% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$41.8 Million0.0% of portfolio
-
Affinity Asset Advisors, LLC New York, NY4.54MShares$39.8 Million1.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.77MShares$33.1 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA3.1MShares$27.2 Million0.4% of portfolio
About Ventyx Biosciences, Inc.
- Ticker VTYX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,527,200
- Market Cap $496M
- Description
- Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...